Heidelberger Zentrum für Herzrhythmusstörungen
Liebe Patientinnen und Patienten, liebe Besucher,
Um optimale Bedingungen für die interdisziplinäre Behandlung von Patienten mit komplexen Herzrhythmusstörungen zu schaffen, wurde Anfang 2017 aus unserer Klinik heraus das Heidelberger Zentrum für Herzrhythmusstörungen gegründet.
Auf den folgenden Seiten wollen wir Ihnen einen kurzen Überblick über das Leistungsspektrum des Heidelberger Zentrums für Herzrhythmusstörungen geben.
Unser Leistungsspektrum erstreckt sich über eine kompetente Beratung beim Vorliegen von Herzrhythmusstörungen, die Nachsorge von Herzschrittmachern und Defibrillatoren, nicht-invasiven Untersuchungsmethoden bis hin zu modernen invasiven Untersuchungstechniken. Wichtige Schwerpunkte sind hierbei die Katheterablation von Herzrhythmusstörungen sowie die Implantation von Herzschrittmachern und Defibrillatoren.
Sollten Sie Rückfragen haben, ein persönliches Informationsgespräch oder eine Routine-/ Kontrolluntersuchung wünschen, nehmen Sie jederzeit gerne Kontakt mit uns auf.
Patientenkontakt
Zur Vereinbarung ambulanter und stationärer Termine wenden Sie sich bitte an die Spezialsprechstunde für Herzrhythmusstörungen.
Bitte bringen Sie zu allen Terminen Ihre Krankenunterlagen (insbesondere evtl. Aufzeichnungen von Herzrhythmusstörungen) mit. Zu Terminen in unseren Ambulanzen müssen Sie in der Regel nicht nüchtern kommen. Sollte dies bei einer ambulant durchgeführten Maßnahme (z.B. Kardioversion) oder einer stationären Aufnahme notwendig sein, wird dies im Vorfeld mit Ihnen abgesprochen. Ob eine Pausierung Ihrer Medikation (z.B. die Einnahme eines Blutverdünnungsmittels) bereits vor Aufnahme sinnvoll ist, wird ebenfalls mit Ihnen vorher abgestimmt.
Publikationen
Klinische Publikationen:
Successful localization and ablation of a Mahaim potential using a high-resolution mapping catheter after a failed conventional ablation attempt. Lugenbiel P, Xynogalos P, Schweizer P, Katus HA, Thomas D, Scholz EP.
Clin Res Cardiol. 2018 Mar 12. doi: 10.1007/s00392-018-1231-5. [Epub ahead of print] No abstract available.
Control of cardiac chronotropic function in patients after heart transplantation: effects of ivabradine and metoprolol succinate on resting heart rate in the denervated heart. Rivinius R, Helmschrott M, Ruhparwar A, Rahm AK, Darche FF, Thomas D, Bruckner T, Ehlermann P, Katus HA, Doesch AO.
Clin Res Cardiol. 2018 Feb;107(2):138-147. doi: 10.1007/s00392-017-1165-3. Epub 2017 Nov 2.
Fully digital data processing during cardiovascular implantable electronic device follow-up in a high-volume tertiary center. Staudacher I, Nalpathamkalam AR, Uhlmann L, Illg C, Seehausen S, Akhavanpoor M, Buchauer A, Geis N, Lugenbiel P, Schweizer PA, Xynogalos P, Zylla MM, Scholz E, Zitron E, Katus HA, Thomas D.
Eur J Med Res. 2017 Oct 11;22(1):41. doi: 10.1186/s40001-017-0284-7.
Comparison of posttransplant outcomes in patients with no, acute, or chronic amiodarone use before heart transplantation. Rivinius R, Helmschrott M, Ruhparwar A, Darche FF, Thomas D, Bruckner T, Katus HA, Doesch AO.
Drug Des Devel Ther. 2017 Jun 19;11:1827-1837. doi: 10.2147/DDDT.S136948. eCollection 2017.
The influence of surgical technique on early posttransplant atrial fibrillation - comparison of biatrial, bicaval, and total orthotopic heart transplantation. Rivinius R, Helmschrott M, Ruhparwar A, Erbel C, Gleissner CA, Darche FF, Thomas D, Bruckner T, Katus HA, Doesch AO.
Ther Clin Risk Manag. 2017 Mar 8;13:287-297. doi: 10.2147/TCRM.S126869. eCollection 2017.
Novel algorithm for accelerated electroanatomic mapping and prediction of earliest activation of focal cardiac arrhythmias using mathematical optimization. Weber T, Katus HA, Sager S, Scholz EP.
Heart Rhythm. 2017 Jun;14(6):875-882. doi: 10.1016/j.hrthm.2017.03.001. Epub 2017 Mar 6.
A Distinct Cardiomyopathy: HCN4 Syndrome Comprising Myocardial Noncompaction, Bradycardia, Mitral Valve Defects, and Aortic Dilation. Schweizer PA, Koenen M, Katus HA, Thomas D.
J Am Coll Cardiol. 2017 Mar 7;69(9):1209-1210. doi: 10.1016/j.jacc.2016.10.085. No abstract available.
Efficacy, High Procedural Safety And Rapid Optimization Of Cryoballoon Atrial Fibrillation Ablation In The Hands Of A New Operator. Scholz E, Lugenbiel P, Schweizer PA, Xynogalos P, Seyler C, Zitron E, Becker R, Katus HA, Thomas D.
J Atr Fibrillation. 2016 Feb 29;8(5):1341. doi: 10.4022/jafib.1341. eCollection 2016 Feb-Mar.
Antiarrhythmic gene therapy - will biologics replace catheters, drugs and devices? Lugenbiel P, Schweizer PA, Katus HA, Thomas D.
Eur J Pharmacol. 2016 Nov 15;791:264-273. doi: 10.1016/j.ejphar.2016.09.001. Epub 2016 Sep 2. Review.
A Simple, Non-Invasive Score to Predict Paroxysmal Atrial Fibrillation. Kallenberger SM, Schmid C, Wiedmann F, Mereles D, Katus HA, Thomas D, Schmidt C.
PLoS One. 2016 Sep 28;11(9):e0163621. doi: 10.1371/journal.pone.0163621. eCollection 2016.
Sex-related outcome of atrial fibrillation ablation: Insights from the German Ablation Registry. Zylla MM, Brachmann J, Lewalter T, Hoffmann E, Kuck KH, Andresen D, Willems S, Eckardt L, Tebbenjohanns J, Spitzer SG, Schumacher B, Hochadel M, Senges J, Katus HA, Thomas D.
Heart Rhythm. 2016 Sep;13(9):1837-44. doi: 10.1016/j.hrthm.2016.06.005. Epub 2016 Jun 8.
Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation. Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Schweizer PA, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO.
Drug Des Devel Ther. 2016 Feb 16;10:677-86. doi: 10.2147/DDDT.S96126. eCollection 2016.
Catheter ablation of atrial fibrillation in patients with concomitant sinus bradycardia-Insights from the German Ablation Registry. Zylla MM, Brachmann J, Lewalter T, Hoffmann E, Kuck KH, Andresen D, Willems S, Hochadel M, Senges J, Katus HA, Thomas D.
J Electrocardiol. 2016 Mar-Apr;49(2):117-23. doi: 10.1016/j.jelectrocard.2015.12.007. Epub 2015 Dec
Long-term outcome of patients with and without super-response to CRT-D. Franke J, Keppler J, Abadei AK, Bajrovic A, Meme L, Zugck C, Raake PW, Zitron E, Katus HA, Frankenstein L.
Clin Res Cardiol. 2016 Apr;105(4):341-8. doi: 10.1007/s00392-015-0926-0. Epub 2015 Oct 23.
It's all in your head: sinus node dysfunction secondary to a sphenoid wing meningioma. Rivinius R, Darche FF, Campos B, Unterberg A, Schweizer L, Thomas D, Katus HA, Schweizer PA.
Herzschrittmacherther Elektrophysiol. 2015 Sep;26(3):300-2. doi: 10.1007/s00399-015-0380-8. Epub 2015 Jul 4.
Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter. Zylla MM, Pohlmeier M, Hess A, Mereles D, Kieser M, Bruckner T, Scholz E, Zitron E, Schweizer PA, Katus HA, Thomas D.
Am J Cardiol. 2015 Mar 1;115(5):635-40. doi: 10.1016/j.amjcard.2014.12.016. Epub 2014 Dec 18.
Effects of β-blocker therapy on electrocardiographic and echocardiographic characteristics of left ventricular noncompaction. Li J, Franke J, Pribe-Wolferts R, Meder B, Ehlermann P, Mereles D, Andre F, Abdelrazek MA, Merten C, Schweizer PA, Becker R, Katus HA, Thomas D.
Clin Res Cardiol. 2015 Mar;104(3):241-9. doi: 10.1007/s00392-014-0778-z. Epub 2014 Oct 21.
The symptom complex of familial sinus node dysfunction and myocardial noncompaction is associated with mutations in the HCN4 channel. Schweizer PA, Schröter J, Greiner S, Haas J, Yampolsky P, Mereles D, Buss SJ, Seyler C, Bruehl C, Draguhn A, Koenen M, Meder B, Katus HA, Thomas D.
J Am Coll Cardiol. 2014 Aug 26;64(8):757-67. doi: 10.1016/j.jacc.2014.06.1155.
Rescue renal sympathetic denervation in a patient with ventricular electrical storm refractory to endo- and epicardial catheter ablation. Scholz EP, Raake P, Thomas D, Vogel B, Katus HA, Blessing E.
Clin Res Cardiol. 2015 Jan;104(1):79-84. doi: 10.1007/s00392-014-0749-4. Epub 2014 Aug 7. No abstract available.
Post cardiac injury syndrome after initially uncomplicated CRT-D implantation: a case report and a systematic review. Sedaghat-Hamedani F, Zitron E, Kayvanpour E, Lorenz HM, Katus HA, Meder B.
Clin Res Cardiol. 2014 Oct;103(10):781-9. doi: 10.1007/s00392-014-0716-0. Epub 2014 Apr 29. Review.
Discriminating atrial flutter from atrial fibrillation using a multilevel model of atrioventricular conduction. Scholz EP, Kehrle F, Vossel S, Hess A, Zitron E, Katus HA, Sager S.
Heart Rhythm. 2014 May;11(5):877-84. doi: 10.1016/j.hrthm.2014.02.013. Epub 2014 Feb 19.
Grundlagenwissenschaftlichen Publikationen
Subtype-specific differentiation of cardiac pacemaker cell clusters from human induced pluripotent stem cells. Schweizer PA, Darche FF, Ullrich ND, Geschwill P, Greber B, Rivinius R, Seyler C, Müller-Decker K, Draguhn A, Utikal J, Koenen M, Katus HA, Thomas D.
Stem Cell Res Ther. 2017 Oct 16;8(1):229. doi: 10.1186/s13287-017-0681-4.
Atrial myofibroblast activation and connective tissue formation in a porcine model of atrial fibrillation and reduced left ventricular function. Lugenbiel P, Wenz F, Govorov K, Syren P, Katus HA, Thomas D.
Life Sci. 2017 Jul 15;181:1-8. doi: 10.1016/j.lfs.2017.05.025. Epub 2017 May 22.
Stretch-activated two-pore-domain (K2P) potassium channels in the heart: Focus on atrial fibrillation and heart failure. Schmidt C, Wiedmann F, Kallenberger SM, Ratte A, Schulte JS, Scholz B, Müller FU, Voigt N, Zafeiriou MP, Ehrlich JR, Tochtermann U, Veres G, Ruhparwar A, Karck M, Katus HA, Thomas D.
Prog Biophys Mol Biol. 2017 Nov;130(Pt B):233-243. doi: 10.1016/j.pbiomolbio.2017.05.004. Epub 2017 May 16.
Inhibition of inwardly rectifying Kir2.x channels by the novel anti-cancer agent gambogic acid depends on both pore block and PIP2 interference. Scherer D, Schworm B, Seyler C, Xynogalos P, Scholz EP, Thomas D, Katus HA, Zitron E.
Naunyn Schmiedebergs Arch Pharmacol. 2017 Jul;390(7):701-710. doi: 10.1007/s00210-017-1372-5. Epub 2017 Apr 2.
Role of plasma membrane-associated AKAPs for the regulation of cardiac IK1 current by protein kinase A. Seyler C, Scherer D, Köpple C, Kulzer M, Korkmaz S, Xynogalos P, Thomas D, Kaya Z, Scholz E, Backs J, Karle C, Katus HA, Zitron E.
Naunyn Schmiedebergs Arch Pharmacol. 2017 May;390(5):493-503. doi: 10.1007/s00210-017-1344-Epub 2017 Mar 22.
Dual Mechanism for Inhibition of Inwardly Rectifying Kir2.x Channels by Quinidine Involving Direct Pore Block and PIP2-interference. Koepple C, Scherer D, Seyler C, Scholz E, Thomas D, Katus HA, Zitron E.
J Pharmacol Exp Ther. 2017 May;361(2):209-218. doi: 10.1124/jpet.116.238287. Epub 2017 Feb 10.
Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy. Schmidt C, Wiedmann F, Zhou XB, Heijman J, Voigt N, Ratte A, Lang S, Kallenberger SM, Campana C, Weymann A, De Simone R, Szabo G, Ruhparwar A, Kallenbach K, Karck M, Ehrlich JR, Baczkó I, Borggrefe M, Ravens U, Dobrev D, Katus HA, Thomas D.
Eur Heart J. 2017 Jun 7;38(22):1764-1774. doi: 10.1093/eurheartj/ehw559.
TREK-1 (K2P2.1) K+ channels are suppressed in patients with atrial fibrillation and heart failure and provide therapeutic targets for rhythm control. Lugenbiel P, Wenz F, Syren P, Geschwill P, Govorov K, Seyler C, Frank D, Schweizer PA, Franke J, Weis T, Bruehl C, Schmack B, Ruhparwar A, Karck M, Frey N, Katus HA, Thomas D.
Basic Res Cardiol. 2017 Jan;112(1):8. doi: 10.1007/s00395-016-0597-7. Epub 2016 Dec 22.
Inhibition of Cardiac Kir Current (IK1) by Protein Kinase C Critically Depends on PKCβ and Kir2.2. Scherer D, Seyler C, Xynogalos P, Scholz EP, Thomas D, Backs J, Andrassy M, Völkers M, Karle CA, Katus HA, Zitron E.
PLoS One. 2016 May 23;11(5):e0156181. doi: 10.1371/journal.pone.0156181. eCollection 2016.
Therapeutic targeting of two-pore-domain potassium (K(2P)) channels in the cardiovascular system. Wiedmann F, Schmidt C, Lugenbiel P, Staudacher I, Rahm AK, Seyler C, Schweizer PA, Katus HA, Thomas D.
Clin Sci (Lond). 2016 May;130(9):643-50. doi: 10.1042/CS20150533. Review.
Upregulation of K(2P)3.1 K+ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation. Schmidt C, Wiedmann F, Voigt N, Zhou XB, Heijman J, Lang S, Albert V, Kallenberger S, Ruhparwar A, Szabó G, Kallenbach K, Karck M, Borggrefe M, Biliczki P, Ehrlich JR, Baczkó I, Lugenbiel P, Schweizer PA, Donner BC, Katus HA, Dobrev D, Thomas D.
Circulation. 2015 Jul 14;132(2):82-92. doi: 10.1161/CIRCULATIONAHA.114.012657. Epub 2015 May 7.
Atrial fibrillation complicated by heart failure induces distinct remodeling of calcium cycling proteins. Lugenbiel P, Wenz F, Govorov K, Schweizer PA, Katus HA, Thomas D.
PLoS One. 2015 Mar 16;10(3):e0116395. doi: 10.1371/journal.pone.0116395. eCollection 2015.
Anesthetic drug midazolam inhibits cardiac human ether-à-go-go-related gene channels: mode of action. Vonderlin N, Fischer F, Zitron E, Seyler C, Scherer D, Thomas D, Katus HA, Scholz EP.
Drug Des Devel Ther. 2015 Feb 16;9:867-77. doi: 10.2147/DDDT.S72765. eCollection 2015.
Inhibition of cardiac Kv1.5 potassium current by the anesthetic midazolam: mode of action. Vonderlin N, Fischer F, Zitron E, Seyler C, Scherer D, Thomas D, Katus HA, Scholz EP.
Drug Des Devel Ther. 2014 Nov 7;8:2263-71. doi: 10.2147/DDDT.S70461. eCollection 2014.
Class III antiarrhythmic drug dronedarone inhibits cardiac inwardly rectifying Kir2.1 channels through binding at residue E224. Xynogalos P, Seyler C, Scherer D, Koepple C, Scholz EP, Thomas D, Katus HA, Zitron E.
Naunyn Schmiedebergs Arch Pharmacol. 2014 Dec;387(12):1153-61. doi: 10.1007/s00210-014-1045-6. Epub 2014 Sep 4.
Modulation of K2P 2.1 and K2P 10.1 K(+) channel sensitivity to carvedilol by alternative mRNA translation initiation. Kisselbach J, Seyler C, Schweizer PA, Gerstberger R, Becker R, Katus HA, Thomas D.
Br J Pharmacol. 2014 Dec;171(23):5182-94. doi: 10.1111/bph.12596. Epub 2014 Aug 28.
Vernakalant activates human cardiac K(2P)17.1 background K(+) channels. Seyler C, Schweizer PA, Zitron E, Katus HA, Thomas D.
Biochem Biophys Res Commun. 2014 Aug 29;451(3):415-20. doi: 10.1016/j.bbrc.2014.07.133. Epub 2014 Aug 7.
Cloning, functional characterization, and remodeling of K2P3.1 (TASK-1) potassium channels in a porcine model of atrial fibrillation and heart failure. Schmidt C, Wiedmann F, Langer C, Tristram F, Anand P, Wenzel W, Lugenbiel P, Schweizer PA, Katus HA, Thomas D.
Heart Rhythm. 2014 Oct;11(10):1798-805. doi: 10.1016/j.hrthm.2014.06.020. Epub 2014 Jun 18.
Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept. Schmidt C, Wiedmann F, Schweizer PA, Katus HA, Thomas D.
Eur J Pharmacol. 2014 Sep 5;738:250-5. doi: 10.1016/j.ejphar.2014.05.056. Epub 2014 Jun 10. Review.
Isoenzyme-specific regulation of cardiac Kv1.5/Kvβ1.2 ion channel complex by protein kinase C: central role of PKCβII. Fischer F, Vonderlin N, Seyler C, Zitron E, Korkmaz S, Szabó G, Thomas D, Katus HA, Scholz EP.
Naunyn Schmiedebergs Arch Pharmacol. 2014 May;387(5):469-76. doi: 10.1007/s00210-014-0965-5. Epub 2014 Feb 28.
HERG K+ channel-dependent apoptosis and cell cycle arrest in human glioblastoma cells. Staudacher I, Jehle J, Staudacher K, Pledl HW, Lemke D, Schweizer PA, Becker R, Katus HA, Thomas D.
PLoS One. 2014 Feb 6;9(2):e88164. doi: 10.1371/journal.pone.0088164. eCollection 2014.
Rotor termination is critically dependent on kinetic properties of I kur inhibitors in an in silico model of chronic atrial fibrillation. Scholz EP, Carrillo-Bustamante P, Fischer F, Wilhelms M, Zitron E, Dössel O, Katus HA, Seemann G.
PLoS One. 2013 Dec 20;8(12):e83179. doi: 10.1371/journal.pone.0083179. eCollection 2013.
Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant--comparison with flecainide. Seyler C, Li J, Schweizer PA, Katus HA, Thomas D.
Eur J Pharmacol. 2014 Feb 5;724:51-7. doi: 10.1016/j.ejphar.2013.12.030. Epub 2013 Dec 27.
Cardiac expression and atrial fibrillation-associated remodeling of K₂p2.1 (TREK-1) K⁺ channels in a porcine model. Schmidt C, Wiedmann F, Tristram F, Anand P, Wenzel W, Lugenbiel P, Schweizer PA, Katus HA, Thomas D.
Life Sci. 2014 Mar 3;97(2):107-15. doi: 10.1016/j.lfs.2013.12.006. Epub 2013 Dec 15.
Functional characterization of zebrafish K2P18.1 (TRESK) two-pore-domain K+ channels. Rahm AK, Wiedmann F, Gierten J, Schmidt C, Schweizer PA, Becker R, Katus HA, Thomas D.
Naunyn Schmiedebergs Arch Pharmacol. 2014 Mar;387(3):291-300. doi: 10.1007/s00210-013-0945-1. Epub 2013 Dec 6.
Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channels. Schmidt C, Wiedmann F, Schweizer PA, Becker R, Katus HA, Thomas D.
Eur J Pharmacol. 2013 Dec 5;721(1-3):237-48. doi: 10.1016/j.ejphar.2013.09.029. Epub 2013 Sep 23.
Inhibition of cardiac Kv1.5 and Kv4.3 potassium channels by the class Ia anti-arrhythmic ajmaline: mode of action. Fischer F, Vonderlin N, Zitron E, Seyler C, Scherer D, Becker R, Katus HA, Scholz EP.
Naunyn Schmiedebergs Arch Pharmacol. 2013 Nov;386(11):991-9. doi: 10.1007/s00210-013-0901-0. Epub 2013 Jul 6.
Provocation of an autoimmune response to cardiac voltage-gated sodium channel NaV1.5 induces cardiac conduction defects in rats. Korkmaz S, Zitron E, Bangert A, Seyler C, Li S, Hegedüs P, Scherer D, Li J, Fink T, Schweizer PA, Giannitsis E, Karck M, Szabó G, Katus HA, Kaya Z.